Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 0.38 |
| ▸ | CPT1A | P50416 | 3/20 | 0.38 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715025 | 0.91 | NAA50 (0.38) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL166241 | 0.85 | TRPV1 (0.42) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL166240 | 0.85 | TRPV1 (0.42) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL10290636 | 0.85 | BAZ2A (0.42) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL6466955 | 0.84 | BAZ2A (0.41) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL475795 | 0.84 | TSHR (0.39) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL3511063 | 0.84 | TSHR (0.39) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL6464489 | 0.84 | POLB (0.39) | CPT2CPT1ACPT1BBAZ2ATSHR | |
| SCHEMBL166175 | 0.83 | USP30 (0.38) | CPT2CPT1ACPT1BMAPTBAZ2A | |
| SCHEMBL716617 | 0.83 | USP30 (0.38) | CPT2CPT1ACPT1BMAPTBAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | CPT2 624/4885CPT1A 743/4885CPT1B 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.